文献速递肝病消化道肿瘤与早癌

接受直接抗病毒药物治疗的丙型肝炎肝硬化患者纳入监测项目后的肝细胞癌发生率

Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
PubMed 文献 · Gastroenterology · 2018-07-19

基于法国ANRS CO12 CirVir队列1270例代偿期活检证实的HCV肝硬化患者,比较接受DAA治疗、IFN治疗后获持续病毒学应答(SVR)及未获SVR三组的肝细胞癌(HCC)发生率。粗3年累积HCC发生率DAA组5.9%、SVR-IFN组3.1%、非SVR组12.7%;经IPTCW加权的Cox分析未发现DAA使用与HCC风险有统计学显著增加相关(HR 0.89;95%CI 0.46-1.73;P=.73)。

要点

  • DAA组粗3年累积HCC发生率5.9%,SVR-IFN组3.1%,非SVR组12.7%(总体P<.001)。
  • 未调整HR为2.03(95%CI 1.07-3.84;P=.030),DAA组 vs SVR-IFN组。
  • IPTCW加权Cox分析显示DAA使用与HCC风险无统计学显著增加相关(HR 0.89;95%CI 0.46-1.73;P=.73)。

核心结论

  • ANRS CO12 CirVir队列分析显示,DAA治疗的肝硬化患者相比IFN治疗后获SVR者所见的HCC发生率表观增加,可由患者特征(年龄、糖尿病、肝功能减退)和筛查强度较低解释。

研究设计与样本

  • 数据来自2006年至2012年在法国35个中心招募的1270例代偿期活检证实的HCV相关肝硬化患者。
  • 患者分为DAA组(n=336)、IFN治疗后获SVR组(SVR-IFN组,n=495)和从未接受DAA且IFN治疗后从未获SVR组(非SVR组,n=439)。
  • 患者纳入基于每6个月超声检查的HCC监测项目,记录临床和生物学数据。
  • 采用以治疗和删失逆概率加权(IPTCW)的时间依赖Cox回归模型评估DAA对至HCC时间的影响。

主要发现

  • 与SVR-IFN组相比,DAA组患者年龄更大、糖尿病或门静脉高压比例更高、肝功能损害更严重。
  • 粗3年累积HCC发生率DAA组5.9%、SVR-IFN组3.1%、非SVR组12.7%(总体P<.001;DAA组 vs SVR-IFN组未调整HR 2.03;95%CI 1.07-3.84;P=.030)。
  • 各组HCC特征相似;在HCC患者中,DAA组接受HCC筛查的频次低于其他两组(P=.002)。
  • 经IPTCW加权Cox分析,未发现DAA使用与HCC风险有统计学显著增加相关(HR 0.89;95%CI 0.46-1.73;P=.73)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Retrospective studies have found an unexpectedly high incidence of hepatocellular carcinoma (HCC) among patients with hepatitis C virus (HCV)-associated cirrhosis who received direct-acting antiviral (DAA) agents. We analyzed data from the ANRS CO12 CirVir cohort to compare the incidence of HCC in patients with cirrhosis who received DAA therapy vs patients treated with interferon (IFN). METHODS: Data were collected from 1270 patients with compensated biopsy-proven HCV-associated cirrhosis recruited from 2006 through 2012 at 35 centers in France. For descriptive purpose, patients were classified as follows: patients who received DAA treatment (DAA group, n = 336), patients who achieved a sustained virologic response (SVR) following an IFN-based regimen (SVR-IFN group, n = 495), or patients who never received DAA treatment and never had an SVR following IFN therapy (non-SVR group, n = 439). The patients were included in HCC surveillance programs based on ultrasound examination every 6 months, and clinical and biological data were recorded. To account for confounding by indication due to differences in patient characteristics at treatment initiation, we constructed a time-dependent Cox regression model weighted by the inverse probability of treatment and censoring (IPTCW) to assess the treatment effects of DAA on time until HCC. RESULTS: Compared with patients in the SVR-IFN group, patients in the DAA group were older, higher proportions had diabetes or portal hypertension, and liver function was more severely impaired. The crude 3-year cumulative incidences of HCC were 5.9% in the DAA group, 3.1% in the SVR-IFN group, and 12.7% in the non-SVR group (overall P < .001; unadjusted hazard ratio [HR] for HCC 2.03; 95% confidence interval [CI] 1.07-3.84; P = .030 for the DAA group vs the SVR-IFN group). HCC characteristics were similar among groups. Among patients with HCC, the DAA group received less-frequent HCC screening than the other 2 groups (P = .002). After Cox analyses weighted by the IPTCW, we found no statistically significant increase in risk of HCC associated with DAA use (HR 0.89; 95% CI 0.46-1.73; P = .73). CONCLUSIONS: Analysis of data from the ANRS CO12 CirVir cohort reveals that the apparent increase in HCC incidence observed in patients with cirrhosis treated with DAAs compared with patients who achieved SVR following an IFN therapy can be explained by patient characteristics (age, diabetes, reduced liver function) and lower screening intensity.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Nahon P, Layese R, Bourcier V, et al. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology. 2018. PMID: 30031138. doi:10.1053/j.gastro.2018.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。